Spyre Therapeutics, Inc. (SYRE)
SYRE Stock Price Chart
Explore Spyre Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SYRE price movements and trends.
SYRE Company Profile
Discover essential business fundamentals and corporate details for Spyre Therapeutics, Inc. (SYRE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Apr 2016
Employees
73.00
Website
https://www.spyre.comCEO
Cameron Turtle
Description
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
SYRE Financial Timeline
Browse a chronological timeline of Spyre Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.71.
Earnings released on 5 May 2026
EPS came in at -$0.74 falling short of the estimated -$0.66 by -12.12%.
Earnings released on 19 Feb 2026
EPS came in at -$0.70 falling short of the estimated -$0.66 by -6.06%, while revenue for the quarter reached $90.49m , missing expectations by -36.65%.
Earnings released on 4 Nov 2025
EPS came in at -$0.15 surpassing the estimated -$0.76 by +80.28%.
Earnings released on 5 Aug 2025
EPS came in at -$0.49 surpassing the estimated -$0.73 by +32.88%.
Earnings released on 8 May 2025
EPS came in at -$0.74 surpassing the estimated -$0.84 by +11.90%.
Earnings released on 28 Feb 2025
EPS came in at -$0.81 surpassing the estimated -$0.89 by +8.99%.
Earnings released on 7 Nov 2024
EPS came in at -$1.36 falling short of the estimated -$0.80 by -70.00%.
Earnings released on 7 Aug 2024
EPS came in at -$0.86 surpassing the estimated -$0.90 by +4.44%.
Earnings released on 9 May 2024
EPS came in at -$1.20 falling short of the estimated -$0.90 by -33.33%.
Earnings released on 29 Feb 2024
EPS came in at -$2.28 falling short of the estimated -$0.48 by -375.00%.
Earnings released on 9 Nov 2023
EPS came in at -$9.34 falling short of the estimated -$0.84 by -1.01k%.
Stock split effective on 8 Sept 2023
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 Aug 2023
EPS came in at -$0.57 falling short of the estimated -$0.03 by -1.53k%, while revenue for the quarter reached $688.00k , beating expectations by +247.47%.
Earnings released on 11 May 2023
EPS came in at -$5.00 falling short of the estimated -$4.50 by -11.11%, while revenue for the quarter reached $198.00k , beating expectations by +7.61%.
Earnings released on 2 Mar 2023
EPS came in at -$5.00 surpassing the estimated -$5.71 by +12.41%, while revenue for the quarter reached $168.00k , beating expectations by +26.00%.
Earnings released on 3 Nov 2022
EPS came in at -$4.33 surpassing the estimated -$6.25 by +30.79%, while revenue for the quarter reached $174.00k , missing expectations by -16.48%.
Earnings released on 4 Aug 2022
EPS came in at -$6.75 surpassing the estimated -$7.95 by +15.05%, while revenue for the quarter reached $625.00k , missing expectations by -11.91%.
Earnings released on 5 May 2022
EPS came in at -$9.25 falling short of the estimated -$8.54 by -8.37%, while revenue for the quarter reached $1.36m , missing expectations by -14.47%.
SYRE Stock Performance
Access detailed SYRE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
